Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning.
Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning.
复制标题
氟-18-BPA-果糖对硼中子俘获处理计划的评估。
DOI：
--
复制
发表时间：
1997
影响因子：
9.3
通讯作者：
K. Hübner
中科院分区：
文献类型：
--
作者：
G. Kabalka;G. T. Smith;J. Dyke;W. S. Reid;C. Longford;T. G. Roberts;N. K. Reddy;E. Buonocore;K. Hübner
无标签
使用4-[10B]硼-苯丙氨酸-果糖(BPA-Fr)的硼中子俘获疗法(BNCT)正处于第二阶段临床试验，以验证BNCT对多形性胶质母细胞瘤和黑色素瘤的治疗作用。成功的BNCT取决于对含硼制剂在肿瘤和正常组织中的分布的了解，目前通过BNCT前手术切除的恶性组织中的硼沉积的化学确认来确定。
方法
我们使用正电子发射计算机断层扫描非侵入性获取18F标记的BPA-Fr类似物在两名多形性胶质母细胞瘤患者体内的药代动力学信息。18F-BPA-Fr团注产生的时间-活度曲线被共同用于模拟用于BNCT治疗的连续输注。
结果
~(18)F-BPA-Fr在PET上的分布与MR所确定的肿瘤分布一致。注射后52分钟，患者1和患者2的18F-BPA-Fr肿瘤与正常脑摄取比值分别为1.9和3.1。胶质母细胞瘤的18F-BPA-Fr摄取率与患者中未标记的BPA-Fr的摄取率平行，这是以前通过对从BNCT前手术活检获得的人胶质母细胞瘤组织的硼分析确定的。
结论
对BPA-Fr生物分布的了解使BNCT前能够计算特定中子暴露下选定剂量BPA-Fr的预期组织剂量。氟-18-BPA-Fr PET能够提供体内BPA-Fr的生物分布数据，这些数据可能被证明对患者选择和BNCT前治疗计划有价值。
UNLABELLED
Boron neutron capture therapy (BNCT) using 4-[10B]boronophenylalanine-fructose (BPA-Fr) is in Phase II clinical trials to validate BNCT as a treatment for glioblastoma multiforme and melanoma. Successful BNCT depends on knowledge of the distribution of boron-containing agents in both tumor and normal tissue as currently determined by chemical confirmation of boron deposition in surgically removed malignant tissue before BNCT.
METHODS
We used PET to noninvasively obtain in vivo information on the pharmacokinetics of the 18F-labeled analog of BPA-Fr in two patients with glioblastoma multiforme. Time-activity curves generated from the bolus injection of 18F-BPA-Fr were coinvolved to simulate a continuous infusion used for BNCT therapy.
RESULTS
Distribution of 18F-BPA-Fr by PET was found to be consistent with tumor as identified by MR imaging. The 18F-BPA-Fr tumor-to-normal brain uptake ratio was 1.9 in Patient 1 and 3.1 in Patient 2 at 52 min after injection. The 18F-BPA-Fr uptake ratio in glioblastoma paralleled that of nonlabeled BPA-Fr seen in patients as previously determined by boron analysis of human glioblastoma tissue obtained from pre-BNCT surgical biopsy.
CONCLUSION
Knowledge of the biodistribution of BPA-Fr enables pre-BNCT calculation of expected tissue dosimetry for a selected dose of BPA-Fr at a specific neutron exposure. Fluorine-18-BPA-Fr PET is capable of providing in vivo BPA-Fr biodistribution data that may prove valuable for patient selection and pre-BNCT treatment planning.
一种图形分析方法，用于估计带有标记代谢物的示踪剂的血液到组织转移常数。
DOI：
--
发表时间：
1996
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
影响因子：
--
作者：
Mankoff,DA;Shields,AF;Graham,MM;Link,JM;Krohn,KA
通讯作者：
Krohn,KA
影响因子：
7.4
作者：
BARTH, RF;ADAMS, DM;ANISUZZAMAN, AKM
通讯作者：
ANISUZZAMAN, AKM